The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Related Posts
Trump will host Walmart, Target, Home Depot execs for tariff meeting
Trump’s aggressive tariff policies have caused uncertainty both for investors and business leaders, many of whom rely heavily on imported goods.
OpenAI says it needs ‘more capital than we’d imagined’ as it lays out for-profit plan
OpenAI said in a blog post Friday that heading into 2025, “we have to becomean enduring company,” which requires changing its structure.
How to play Disney’s Hulu deal, according to Creekmur Wealth Advisors’ investment chief
John Creekmur, chief investment officer at Creekmur Wealth Advisors, joined CNBC’s ‘Power Lunch’ to review his takes on three stocks.